Biotypes in Psychosis: Has the RDoC Era Arrived?
- 1 April 2016
- journal article
- editorial
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 173 (4) , 313-314
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for PsychosisAmerican Journal of Psychiatry, 2016
- Identification of Distinct Psychosis Biotypes Using Brain-Based BiomarkersAmerican Journal of Psychiatry, 2016
- D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trialThe Lancet Psychiatry, 2015
- Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosisSchizophrenia Research, 2015
- Etiologic, Phenomenologic, and Endophenotypic Overlap of Schizophrenia and Bipolar DisorderAnnual Review of Clinical Psychology, 2015
- Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of SchizophreniaAmerican Journal of Psychiatry, 2015
- Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With SchizophreniaJAMA Psychiatry, 2013
- Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a DriverNeuron, 2013
- Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the ratPsychopharmacology, 2008
- Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions2007